← Back

Lanzhou Foci Pharmaceutical Co Ltd

Lanzhou Foci Pharmaceutical Co., Ltd. is engaged in the research, development, production, and sales of traditional Chinese medicines and health products in China. Its products are offered in dosage forms such as pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. The company also plants and sells Chinese medicinal materials, processes and sells Chinese herbal medicine pieces, produces and sells medical devices, and provides technology development, technical, and inspection and testing services. Founded in 1929 and based in Lanzhou, China, it exports its products and operates as a subsidiary of Lanzhou Foci Pharmaceutical Industry Development Group Co., Ltd.

Country
Price · split & dividend adjusted
News & notes moving 002644.CS
002644.CS▲4

Foci Pharmaceutical's 2026 interim net profit reaches 39.7385 million yuan, up 32% year-on-year

Foci Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 39.7385 million yuan, up 32.00% from the same period last year. Total operating revenue was 440 million yuan, up 2.55% year-on-year. Net cash inflow from operating activities was 160 million yuan, up 796.82% year-on-year, marking three consecutive years of growth. The company's latest asset-liability ratio was 28.13%, gross margin was 33.19%, return on equity was 2.13%, and diluted earnings per share was 0.08 yuan.
002644.CS ▲
Jiemian·29dRead more →
002644.CS▲

Foci Pharmaceutical Plans Cash Dividend of 0.6 Yuan per 10 Shares

Foci Pharmaceutical announced plans to distribute a cash dividend of 0.6 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 30.64 million yuan. In the first half of 2026, the company achieved revenue of 440 million yuan and net profit attributable to the parent of 39.74 million yuan.
002644.CS ▲
财中社·30dRead more →
002644.CS

Foci Pharmaceutical Board Secretary Wang Junhui Resigns, An Wenting Takes Over

Foci Pharmaceutical announced that Board Secretary Wang Junhui has resigned for personal reasons and will no longer hold any position in the company. The company convened a board meeting on July 28, 2026, and decided to appoint An Wenting as the new Board Secretary, with a term lasting until the end of the eighth board's tenure. An Wenting holds the Board Secretary qualification certificate from the Shenzhen Stock Exchange and possesses relevant professional capabilities and industry experience. In the first quarter of 2026, Foci Pharmaceutical achieved revenue of 212 million yuan and a net profit attributable to the parent company of 22.66 million yuan.
002644.CS
财中社·53dRead more →
© 2026 MarketDXAsset